Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operations ...

Excluding contributions from compounded semaglutide, Hims & Hers said it expects it weight loss offering will generate at least $725 million in revenue in 2025. Hims & Hers also offers treatments ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings.

However, there’s significant risk. HIMS stock has soared 110% in less than two months since the beginning of the year, partly driven by its offering of compounded weight loss medications as an ...

Both medications contain semaglutide, a GLP-1 drug experiencing soaring demand. Hims & Hers’ offerings will now be limited to personalized treatments, in compliance with the applicable laws and ...

Hims & Hers in a regulatory filing said while it believes there are paths to continue offering access to certain compounded GLP-1s after the shortage ends, it cannot "guarantee that we will be ...

But with lofty expectations about its remaining anti-obesity offering still baked in to the share price, more pain could be ahead. Shares sank early Tuesday, a day after Hims said it would stop ...

More Information about HIMS' New Offering By acquiring Sigmund NJ LLC, known as Trybe Labs, Hims & Hers will be able "to support at-home blood draws and more comprehensive whole body testing," HIMS ...